Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.

The combination of mitozantrone, methotrexate and mitomycin (3M) gives a response rate of around 50% in patients with advanced breast cancer. The predominant toxicity is haematological. In this study, previously untreated patients were given 3M with increasing doses of mitozantrone (7-14 mg m-2) wit...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Brien, M. E., Nicolson, M., Montes, A., Tidy, A., Ashley, S., Powles, T. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033556/
https://www.ncbi.nlm.nih.gov/pubmed/7524607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033556/
https://www.ncbi.nlm.nih.gov/pubmed/7524607

Ejemplares similares